• Toremifene vs. Tamoxifen: Efficacy in Advanced Breast Cancer

  2026-06-13

  This systematic review rigorously compares toremifene and tamoxifen, two selective estrogen receptor modulators, for the treatment of advanced breast cancer. The study offers detailed evidence on efficacy, disease progression, and adverse event profiles, providing clarity for researchers and clinicians evaluating hormone receptor modulation strategies.

• Central Neural Circuits in Opioid-Induced Mechanical Hyperse

  2026-06-12

  Yin et al. (2024) delineate a brain-to-spinal opioid pathway mediating mechanical opioid-induced hypersensitivity (OIH) and tolerance in mice, revealing a circuit-level mechanism involving MOR-, Dyn-, and KOR-GABA neurons. These findings offer a refined map for targeting mechanical pain modulation and inform strategies for dissecting opioid receptor signaling in translational research.

• C8-HSL: Translational Leverage in Infection and Cancer Resea

  2026-06-12

  N-octanoyl-L-Homoserine lactone (C8-HSL) is emerging as a pivotal tool for researchers aiming to bridge infection biology, microbial pathogenicity, and cancer risk studies. This thought-leadership article unpacks the mechanistic landscape of C8-HSL, explores its translational applications, and offers strategic guidance on experimental design—highlighting how APExBIO’s C8-HSL sets new standards for precision research.

• Dacomitinib (PF-00299804): Applied Protocols in Cancer Resea

  2026-06-11

  Dacomitinib (PF-00299804) empowers researchers to dissect ErbB signaling and resistance mechanisms in cancer models, enabling robust apoptosis and cell cycle studies across diverse tumor types. This article details practical workflows, protocol parameters, and troubleshooting strategies to maximize experimental impact with this irreversible pan-HER inhibitor.

• SCUBE3 Antibody Targeting Blocks Oncogenic and Immune Pathwa

  2026-06-11

  This study identifies secretory SCUBE3 as a dual driver of oncogenic signaling and immune evasion in cancer. Antibody-mediated targeting of SCUBE3 disrupts its interactions with key receptor pathways, suppresses tumor growth, and restores antitumor immunity, providing a promising therapeutic strategy for diverse malignancies.

• Fasudil (HA-1077) HCl: Precision ROCK Inhibition Workflows

  2026-06-10

  Fasudil (HA-1077) HCl stands out for its selective, potent inhibition of the Rho/ROCK pathway, enabling robust modulation of cell migration, proliferation, and apoptosis in advanced disease models. This article navigates practical protocols, troubleshooting strategies, and the pivotal role of pathway crosstalk—equipping researchers with actionable insights for maximizing the impact of APExBIO’s Fasudil in translational research.

• FK866 (APO866): Precision NAMPT Inhibition in AML Research

  2026-06-10

  FK866 (APO866) empowers hematologic cancer research with unparalleled specificity as a NAMPT inhibitor, enabling selective targeting of NAD metabolism in acute myeloid leukemia and beyond. This guide distills advanced workflows, troubleshooting insights, and translational strategies to maximize experimental success with APExBIO's flagship compound.

• Patient-Derived Gastric Cancer Assembloids Enhance Drug Test

  2026-06-09

  This study presents a novel assembloid model integrating matched tumor organoids with stromal cell subpopulations from gastric cancer patients, enabling more physiologically relevant investigation of tumor–stroma interactions and drug responses. The approach highlights the importance of microenvironmental complexity in preclinical drug screening and resistance mechanism studies.

• Prochlorperazine in Translational Research: Mechanistic Dept

  2026-06-09

  Explore the advanced pharmacological profile of Prochlorperazine, a dopamine D2 receptor antagonist, and its unique translational research applications. This article provides a mechanistic deep dive, practical protocol guidance, and cross-domain insights not covered elsewhere.

• Cyclosporin A Beyond Immunosuppression: Multi-Modal Research

  2026-06-08

  Explore the multifaceted mechanisms and advanced research applications of Cyclosporin A, a pivotal immunosuppressant and cyclophilin inhibitor. This article uniquely connects its mitochondrial, apoptotic, and viral modulation effects to practical experimental workflows.

• Integrating ROS Assay Kits into Cutting-Edge Immunotoxicity

  2026-06-08

  Discover how the Reactive Oxygen Species Assay Kit leverages dihydroethidium (DHE) probes for advanced oxidative stress analysis in immunotoxicity studies—bridging mechanistic insights and practical assay design for redox biology.

• AZD2461: A Novel PARP Inhibitor for Advanced Breast Cancer R

  2026-06-07

  AZD2461 is a novel PARP inhibitor with nanomolar potency and the unique ability to overcome Pgp-mediated drug resistance. It induces robust cytotoxicity and G2 phase cell cycle arrest in breast cancer models. Its performance is supported by in vitro and in vivo benchmarks, making it a valuable tool for DNA repair pathway modulation.

• Toremifene vs Tamoxifen in Advanced Breast Cancer: Systemati

  2026-06-06

  A Cochrane systematic review rigorously compared toremifene and tamoxifen as oral selective estrogen receptor modulators for advanced breast cancer. The meta-analysis revealed no clinically significant differences in efficacy or safety between the two agents, informing evidence-based choices in hormone receptor modulation strategies.

• Redox Precision in Translation: Bardoxolone Methyl’s Strateg

  2026-06-05

  This article provides translational researchers with a mechanistic and strategic synthesis on leveraging Bardoxolone methyl (CDDO methyl ester) for redox pathway modulation. Integrating recent breakthroughs in thioredoxin system biology and translational oncology, it differentiates itself by providing evidence-based guidance on experimental design, competitive positioning, and emerging combinatorial strategies—bridging foundational biochemistry with actionable translational insights.

• 17-AAG (Tanespimycin): Applied HSP90 Inhibition Workflows

  2026-06-05

  17-AAG (Tanespimycin) empowers researchers to dissect HSP90-dependent oncogenic pathways, yielding precise, reproducible cytotoxicity and apoptosis data in diverse cancer models. This in-depth guide translates new discoveries in regulated cell death and membrane dynamics into actionable experimental protocols, troubleshooting strategies, and advanced applications—anchored by APExBIO’s proven reagent quality.

15986 records 1/1066 page Next 12345 下5页 Last page